Sangui Biotech International Inc
Sangui Biotech International, Inc., through its subsidiaries, engages in the manufacturing and sales of wound treatment and cosmetic products. The company offers artificial oxygen carriers comprising oxygen carrying blood additives and oxygen carrying blood volume substitutes; nano formulations for the regeneration of skin; chitoskin wound pads; Hemospray, a hemoglobin based wound spray; and woun… Read more
Sangui Biotech International Inc (SGBI) - Total Assets
Latest total assets as of March 2024: $89.70K USD
Based on the latest financial reports, Sangui Biotech International Inc (SGBI) holds total assets worth $89.70K USD as of March 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Sangui Biotech International Inc - Total Assets Trend (2000–2023)
This chart illustrates how Sangui Biotech International Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Sangui Biotech International Inc - Asset Composition Analysis
Current Asset Composition (June 2023)
Sangui Biotech International Inc's total assets of $89.70K consist of 46.1% current assets and 53.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 3.3% |
| Accounts Receivable | $27.43K | 30.2% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2000–2023)
This chart illustrates how Sangui Biotech International Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Sangui Biotech International Inc's current assets represent 46.1% of total assets in 2023, a decrease from 95.2% in 2000.
- Cash Position: Cash and equivalents constituted 3.3% of total assets in 2023, down from 89.7% in 2000.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2000.
- Asset Diversification: The largest asset category is accounts receivable at 30.2% of total assets.
Sangui Biotech International Inc Competitors by Total Assets
Key competitors of Sangui Biotech International Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Sangui Biotech International Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Sangui Biotech International Inc generates 1.02x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Sangui Biotech International Inc is currently not profitable relative to its asset base.
Sangui Biotech International Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.05 | 0.04 | 0.12 |
| Quick Ratio | 0.05 | 0.04 | 0.12 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-1.04 Million | $ -988.12K | $ -591.99K |
Sangui Biotech International Inc - Advanced Valuation Insights
This section examines the relationship between Sangui Biotech International Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 46.44 |
| Latest Market Cap to Assets Ratio | 0.40 |
| Asset Growth Rate (YoY) | -30.5% |
| Total Assets | $90.94K |
| Market Capitalization | $36.51K USD |
Valuation Analysis
Below Book Valuation: The market values Sangui Biotech International Inc's assets below their book value (0.40 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Sangui Biotech International Inc's assets decreased by 30.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Sangui Biotech International Inc (2000–2023)
The table below shows the annual total assets of Sangui Biotech International Inc from 2000 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-06-30 | $90.94K | -30.47% |
| 2022-06-30 | $130.79K | -2.49% |
| 2021-06-30 | $134.12K | +7.02% |
| 2020-06-30 | $125.33K | +58.70% |
| 2019-06-30 | $78.97K | -22.60% |
| 2018-06-30 | $102.03K | +8.80% |
| 2017-06-30 | $93.77K | -15.08% |
| 2016-06-30 | $110.42K | -9.57% |
| 2015-06-30 | $122.10K | -53.14% |
| 2014-06-30 | $260.59K | -50.17% |
| 2013-06-30 | $522.98K | -53.63% |
| 2012-06-30 | $1.13 Million | +490.69% |
| 2011-06-30 | $190.91K | +91.78% |
| 2010-06-30 | $99.55K | 0.00% |
| 2009-06-30 | $99.55K | -91.65% |
| 2008-06-30 | $1.19 Million | +621.54% |
| 2007-06-30 | $165.19K | +33.32% |
| 2006-06-30 | $123.91K | -79.45% |
| 2005-06-30 | $603.01K | 0.00% |
| 2004-06-30 | $603.01K | -72.71% |
| 2003-06-30 | $2.21 Million | -52.29% |
| 2002-06-30 | $4.63 Million | -33.17% |
| 2001-06-30 | $6.93 Million | -28.14% |
| 2000-06-30 | $9.65 Million | -- |